LRRC34: A Protein Target for Drug Development and Disease Treatment

Target Name: LRRC34

NCBI ID: G151827

LRRC34

LRRC34: A Protein Target for Drug Development and Disease Treatment

LRRC34, also known as Leucine rich repeat containing 34, is a protein that is found in various cell types throughout the body. It is made up of a repeating sequence of 20 amino acids, which consists of 18 leucine residues and two cysteine residues. LRRC34 is known for its role in the regulation of various cellular processes, including cell signaling, DNA replication, and stress response.

Recent studies have suggested that LRRC34 may have potential as a drug target or biomarker. For example, LRRC34 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, LRRC34 has been shown to be overexpressed or downregulated in various diseases, which could make it a useful biomarker for monitoring disease progression or as a target for therapeutic intervention.

One of the potential reasons for the interest in LRRC34 as a drug target is its role in the regulation of cellular signaling pathways. LRRC34 has been shown to play a negative role in the regulation of the PI3K/Akt signaling pathway, which is involved in various cellular processes, including cell survival, proliferation, and angiogenesis. This suggests that LRRC34 may be a useful target for drugs that are designed to inhibit this pathway.

Another potential reason for the interest in LRRC34 as a drug target is its role in the regulation of DNA replication. LRRC34 has been shown to play a role in the regulation of DNA replication, which is important for the maintenance of cellular genetic diversity and for the development of cancer. Additionally, LRRC34 has been shown to be involved in the regulation of DNA repair, which is important for the maintenance of cellular genetic stability and for the development of age-related diseases.

In addition to its role in cellular signaling pathways, LRRC34 has also been shown to be involved in the regulation of various biomarkers, including the expression of genes involved in inflammation, stress response, and apoptosis. This suggests that LRRC34 may be a useful target for drugs that are designed to modulate these pathways and are associated with various diseases.

LRRC34 has also been shown to be involved in the regulation of cellular stress response. LRRC34 has been shown to play a role in the regulation of cellular stress response, which is important for the development and progression of stress-induced diseases. Additionally, LRRC34 has been shown to be involved in the regulation of cellular apoptosis, which is important for the regulation of cell numbers and for the development of diseases associated with cellular dysfunction.

Overall, LRRC34 is a protein that has been shown to play a role in various cellular processes that are important for the development and progression of diseases. Its potential as a drug target or biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of LRRC34 in disease and to develop safe and effective drugs that target this protein.

Protein Name: Leucine Rich Repeat Containing 34

Functions: Highly expressed in stem cells where it may be involved in regulation of pluripotency. In embryonic stem cells (ESCs), important for normal expression of the pluripotency regulators POU5F1/OCT4 and KLF4. Also important for expression of the ectodermal marker gene NES and the endodermal marker gene GATA4. Promotes stem cell proliferation in vitro

The "LRRC34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets